ANCER®, THE "ANSWER" TO CANCER
Superior Neo-Epitope Selection Powered by Advanced In Silico Machine-Learning Algorithms
Traditional Neo-Epitope selection methods are cumbersome, non-validated and generate Neo-Epitopes that are mostly non-immunogenic or that can potentially trigger either an immune suppressive response or an adverse immune related adverse event.
Ancer® neoantigen in silico prediction platform, leverages licensed EpiMatrix® and JanusMatrix™ algorithms, state-of-the-art tools that have been externally validated in several prospective vaccine studies and that are broadly utilized worldwide by pharmaceutical and biotechnology companies. Ancer® is designed to enable the discovery of highly immunogenic neoantigens for precision cancer immunotherapies. It is integrated into an end-to-end, GMP ready, robust and already established commercial-grade platform.
In addition, Ancer® (via JanusMatrix™) enables the rapid, in silico, discovery and removal of both:
-
The "Self-Like" inhibitory Treg neoepitopes that may trigger an immune suppressive response.
-
The “Self-Like” cross-reactive neoepitopes that may trigger an immune related adverse event.
Ancer® is differentiated from other Neo-Epitope prediction tools (the other tools are based on the publicly available IEDB and NetMHC based algorithms which we have shown to be inaccurate). Note that most approaches combine mass spectrometry or elution methods to increase the accuracy of their predictive algorithms. These additional steps are cumbersome and labor intensive. Ancer® does not require any other epitope selection methods, it is 100% in silico.
Importantly, head-to-head comparisons have been performed and consistently show a significantly higher epitope prediction accuracy. Thus, leading to potentially more potent and precise therapeutic cancer immunotherapies.
ANCER® is licensed by EVA Therapeutics from EpiVax, Inc.
JANUSMATRIX
In silico removal of inhibitory antigens
The JanusMatrix algorithm, included in the Ancer platform, is a key differentiator of our technology. JanusMatrix, named after Janus — the Roman god of duality, is used to identify putative epitopes which have the potential to cross-react with the human genome [4].
In the case of vaccines, cross conservation between human epitopes and the antigenic epitopes may indicate that such a candidate utilizes immune camouflage, thereby evading the immune response and making for an ineffective vaccine.
